EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

EGFR-targeted drugs and resistance mechanisms in non–small cell lung cancer: Molecular insights and emerging therapeutic strategies

Suleiman Ibrahim Mohammad, Asokan Vasudevan iD, Tareq Nayef AlRamadneh iD, Ihsan K Jasim, Tushar B Gajjar, Malathi Hanumanthayya, Sandeep Kumar Shukla, Navin Kumar Tailor, Mirza R Baig iD, Zahraa Abbas

DARU Journal of Pharmaceutical Sciences · 09.11.2026 · 35 (1)

DOI: 10.1007/s40199-026-00690-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 09.11.2026. Verfasst von Suleiman Ibrahim Mohammad und 9 weiteren Autor:innen. Beteiligte Einrichtung: INTI International University, Nilai, Negeri Sembilan, 71800, Malaysia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 190 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) plays a pivotal role in the pathogenesis and progression of non-small cell lung cancer (NSCLC), with activating mutations serving as key determinants of sensitivity to targeted therapies. The prevalence and spectrum of EGFR mutations are influenced by histology, ethnicity, and environmental factors, encompassing common alterations such as exon 19 deletions and the L858R point mutation, as well as uncommon variants including exon 20 insertions, kinase domain duplications, and other rare substitutions. These molecular distinctions underlie differential responses to first-, second-, and third-generation tyrosine kinase inhibitors (TKIs), emphasizing the necessity of precise molecular profiling for individualized treatment selection. Although EGFR TKIs initially produce robust responses, resistance inevitably develops via on-target mutations (e.g., T790M, C797S), activation of bypass signaling pathways, co-occurring genetic alterations, and histologic or phenotypic transformation, challenging long-term disease control. Contemporary strategies to overcome resistance include combination therapies integrating TKIs with MEK, MET, or AXL inhibitors, antibody-based therapeutics, bispecific antibodies, antibody-drug conjugates, and emerging multifunctional biologics. Additionally, immunomodulatory interventions and nanotechnology-based delivery systems enhance anti-tumor efficacy while mitigating resistance. Non-invasive monitoring techniques, such as liquid biopsies, circulating tumor DNA profiling, and advanced imaging modalities, enable longitudinal assessment of mutation dynamics and therapeutic response, informing adaptive, precision-guided treatment strategies. This review synthesizes current knowledge on EGFR mutations, resistance mechanisms, and emerging therapeutic approaches in NSCLC, highlighting the integration of molecular, immunologic, and technological modalities to improve patient outcomes and advance precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsHumansErbB ReceptorsMutationMolecular Targeted Therapy

Stichwörter der Autor:innen

EGFRNSCLCResistanceTKIsTherapy

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, human

Autor:innen und Institutionen

  • INTI International University, Nilai, Negeri Sembilan, 71800, Malaysia.
  • Faculty of Business and Communications, INTI International University, Persiaran Perdana BBN Putra Nilai, Nilai, Negeri Sembilan, 71800, Malaysia.
  • School of Management, Department of Management Studies, Vel Tech Rangarajan Dr. Sagunthala RandD Institute of Science and Technology, University in Morai, Chennai, Tamil Nadu, 600062, India.
  • Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
  • College of Pharmacy, Department of Pharmaceutical Sciences, AL-Turath University, Baghdad, Iraq.
  • Faculty of Pharmacy, Gokul Global University, Sidhpur, Gujarat, India.

ORCID-Profile: Asokan Vasudevan, Tareq Nayef AlRamadneh, Mirza R Baig

Zitieren

APA

Mohammad, S. I., Vasudevan, A., AlRamadneh, T. N., Jasim, I. K., Gajjar, T. B., Hanumanthayya, M., Shukla, S. K., Tailor, N. K., R Baig, M., & Abbas, Z. (2026). EGFR-targeted drugs and resistance mechanisms in non–small cell lung cancer: Molecular insights and emerging therapeutic strategies. DARU Journal of Pharmaceutical Sciences, 35(1). https://doi.org/10.1007/s40199-026-00690-2

Vancouver

Mohammad SI, Vasudevan A, AlRamadneh TN, Jasim IK, Gajjar TB, Hanumanthayya M, et al. EGFR-targeted drugs and resistance mechanisms in non–small cell lung cancer: Molecular insights and emerging therapeutic strategies. DARU Journal of Pharmaceutical Sciences. 2026;35(1). doi:10.1007/s40199-026-00690-2

BibTeX
@article{Mohammad2026,
  author = {Mohammad, Suleiman Ibrahim and Vasudevan, Asokan and AlRamadneh, Tareq Nayef and Jasim, Ihsan K and Gajjar, Tushar B and Hanumanthayya, Malathi and Shukla, Sandeep Kumar and Tailor, Navin Kumar and R Baig, Mirza and Abbas, Zahraa},
  title = {EGFR-targeted drugs and resistance mechanisms in non–small cell lung cancer: Molecular insights and emerging therapeutic strategies},
  journal = {DARU Journal of Pharmaceutical Sciences},
  year = {2026},
  volume = {35},
  number = {1},
  doi = {10.1007/s40199-026-00690-2}
}
Kostenlos starten →